Transdermal delivery of tolterodine tartrate for overactive bladder treatment: In vitro and in vivo evaluation

Rajabalaya, Rajan; Mun, Chung Yee; Chellian, Jestin; Chakravarthi, Srikumar; David, Sheba R.

doi:10.1515/acph-2017-0027

Abstract

The purpose of the study was to develop a transdermal tolterodine tartrate (TT) patch and to analyse its efficacy for overactive bladder (OAB) treatment. Patches were prepared using various polymers and plasticizers via the solvent casting method. The patches were characterized for tensile strength, thickness, moisture content, modulus of elasticity and water absorption capacity. Differential scanning calorimetry and Fourier transform infrared analyses were also performed. To determine patch effectiveness, in vitro release, permeation and animal studies were performed. The patches showed satisfactory percentage of release, up to 89.9 %, and their mechanical properties included thickness (0.10–0.15 mm), tensile strength (4.62–9.98 MPa) and modulus of elasticity (20–29 MPa). There were no significant interactions between TT and other excipients. Animal studies indicated that the TT patch reduced the incidence of side effects; however, studies of longer duration are required to determine the effectiveness in treating OAB.

References

1. A. J. Wein and E. S. Rovner, Definition and epidemiology of overactive bladder, Urology60 (2002) 7–12; DOI: 10.1016/S0090-4295(02)01784-3.10.1016/S0090-4295(02)01784-3
Search in Google Scholar Back to article
2. S. Tyagi, C. A. Thomas, Y. Hayashi and M. B. Chancellor, The overactive bladder: epidemiology and morbidity, Urol. Clin. North Am.33 (2006) 433–438; DOI: 10.1016/j.ucl.2006.06.002.10.1016/j.ucl.2006.06.002
Search in Google Scholar Back to article
3. H. Hashim and P. Abrams, Drug treatment of overactive bladder: Efficacy, cost and quality-of-life considerations, Drugs64 (2004) 1643–1656; DOI: 10.2165/00003495-200464150-00003.10.2165/00003495-200464150-00003
Search in Google Scholar Back to article
4. F. Haab, L. Stewart and P. Dwyer, Darifenacin, an M₃ selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder, Eur. Urol.45 (2004) 420–429; DOI: 10.1016/j.eururo.2004.01.008.10.1016/j.eururo.2004.01.008
Search in Google Scholar Back to article
5. P. K. Kiptoo, M. O. Hamad, P. A. Crooks and A. L. Stinchcomb, Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion, J. Control. Release113 (2006) 137–145; DOI: 10.1016/j.jconrel.2006.04.003.10.1016/j.jconrel.2006.04.003
Search in Google Scholar Back to article
6. K. Maman, S. Aballea, J. Nazir, K. Desroziers, M. E. Neine, E. Siddiqui, I. Odeyemi and Z. Hakimi, Comparative efficacy and safety of medical treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison, Eur. Urol.65 (2014) 755–765; DOI: 10.1016/j.eururo.2013.11.010.10.1016/j.eururo.2013.11.010
Search in Google Scholar Back to article
7. T. Omotosho and C. C. G. Chen, Update on tolterodine extended-release for treatment of overactive bladder, Open Access J. Urol. (2010) 185–191; DOI: 10.2147/OAJU.S7232.10.2147/OAJU.S7232
Search in Google Scholar Back to article
8. P. Rama Rao, M. N. Reddy, S. Ramakrishna and P. V Diwan, Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits, Eur. J. Pharm. Biopharm.56 (2003) 81–85; DOI: 10.1016/S0939-6411(03)00038-9.10.1016/S0939-6411(03)00038-9
Search in Google Scholar Back to article
9. D. Clemett and B. Jarvis, Tolterodine: a review of its use in the treatment of overactive bladder, Drugs Aging18 (2001) 277–304.
Search in Google Scholar Back to article
10. D. Gautam, T. S. Heard, Y. Cui, G. Miller, L. Bloodworth and J. Wess, Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice, Mol. Pharmacol.66 (2004) 260–267; DOI: 10.1124/mol.66.2.260.10.1124/mol.66.2.26015266016
Search in Google Scholar Back to article
11. A. Arora, E. Kisak, P. Karande, J. Newsam and S. Mitragotri, Multicomponent chemical enhancer formulations for transdermal drug delivery: more is not always better, J. Control. Release144 (2010) 175–180; DOI: 10.1016/j.jconrel.2010.02.015.10.1016/j.jconrel.2010.02.01520153789
Search in Google Scholar Back to article
12. V. W. Nitti, S. Sanders, D. R. Staskin, R. R. Dmochowski, P. K. Sand, S. MacDiarmid and H. I. Maibach, Transdermal delivery of drugs for urologic applications: Basic principles and applications, Urology67 (2006) 657–664; DOI: 10.1016/j.urology.2005.11.039.10.1016/j.urology.2005.11.03916618554
Search in Google Scholar Back to article
13. M. Akhlaq, M. S. Arshad, A. M. Mudassir, A. Hussain, I. Kucuk, R. Haj-Ahmad, M. Rasekh and Z. Ahmad, Formulation and evaluation of anti-rheumatic dexibuprofen transdermal patches: a quality-by-design approach, J. Drug Target.24 (2016) 603–612; DOI: 10.3109/1061186X.2015.1116538.10.3109/1061186X.2015.111653826586147
Search in Google Scholar Back to article
14. L. Zhao, Y. Li, L. Fang, Z. He, X. Liu, L. Wang, Y. Xu and C. Ren, Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation, Int. J. Pharm.374 (2009) 73–81; DOI: 10.1016/j.ijpharm.2009.03.005.10.1016/j.ijpharm.2009.03.00519446762
Search in Google Scholar Back to article
15. F. Sun, C. Sui, Y. Zhou, X. Liu, Y. Shi, Y. Wu and Y. Li, Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder, Int. J. Pharm.454 (2013) 532–538; DOI: 10.1016/j.ijpharm.2013.07.041.10.1016/j.ijpharm.2013.07.04123891744
Search in Google Scholar Back to article
16. A. H. Elshafeey, A. O. Kamel and M. M. Fathallah, Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies, Pharm. Res.26 (2009) 2446–2453; DOI: 10.1007/s11095-009-9956-5.10.1007/s11095-009-9956-519697106
Search in Google Scholar Back to article
17. R. Rajabalaya, S. R. David, J. Chellian, G. Xin Yun and S. Chakravarthi, Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder, Drug Deliv.23 (2016) 1578–1587; DOI: 10.3109/10717544.2015.1116027.10.3109/10717544.2015.111602726634274
Search in Google Scholar Back to article
18. R. Rajabalaya, G. Leen, J. Chellian, S. Chakravarthi and S. David, Tolterodine tartrate proniosomal gel transdermal delivery for overactive bladder, Pharmaceutics8 (2016) 27; DOI: 10.3390/pharmaceutics8030027.10.3390/pharmaceutics8030027503944627589789
Search in Google Scholar Back to article
19. R. Rajabalaya, S. R. N. David, J. Khanam and A. Nanda, Studies on the effect of plasticizer on in vitro release and ex vivo permeation from Eudragit E 100 based chlorpheniramine maleate matrix type transdermal delivery system, J. Excipients Food Chem.1 (2010) 3–12.
Search in Google Scholar Back to article
20. S. R. N. David, M. S. Hui, C. F. Pin, F. Y. Ci and R. Rajabalaya, Formulation and in vitro evaluation of ethosomes as vesicular carrier for enhanced topical delivery of isotretinoin, Int. J. Drug Deliv.5 (2013) 28–34.
Search in Google Scholar Back to article
21. T. Oki, A. Toma-Okura and S. Yamada, Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion, J. Pharmacol. Exp. Ther.316 (2006) 1137–1145; DOI: 10.1124/jpet.105.094508.10.1124/jpet.105.09450816282521
Search in Google Scholar Back to article
22. R. Rajabalaya, S. R. N. David, J. Khanam and A. Nanda, Effect of platicizers on in vitro release and ex vivo permeation of chlorpheniramine maleate from ethyl cellulose polyvinyl pyrrolidone based matrix patches, Farmacia61 (2013) 975–990.
Search in Google Scholar Back to article
23. S. David, R. Rajabalaya and E. Zhia, Development and in vitro evaluation of self-adhesive matrix-type transdermal delivery system of ondansetron hydrochloride, Trop. J. Pharm. Res.14 (2015) 211–218; DOI: 10.4314/tjpr.v14i2.4.10.4314/tjpr.v14i2.4
Search in Google Scholar Back to article
24. R. Rajabalaya, J. Khanam and A. Nanda, Design of a matrix patch formulation for long-acting permeation of diclofenac potassium, Asian J. Pharm. Sci.3 (2008) 30–39.
Search in Google Scholar Back to article
25. R. Rajabalaya, T. W. Xian and S. R. N. David, Preparation and evaluation of transdermal drug delivery of ondansetron hydrochloride: effect of vegetable oils as permeation enhancer, Lat. Am. J. Pharm.31 (2012) 1005–1012.
Search in Google Scholar Back to article
26. R. Rajabalaya, H. Q. Choo and S. R. N. David, Development and in vitro evaluation of matrix type transdermal delivery of ondansetron hydrochloride, Int. J. Drug Deliv.4 (2012) 125–133.
Search in Google Scholar Back to article
27. J. Siepmann, F. Lecomte and R. Bodmeier, Diffusion-controlled drug delivery systems: calculation of the required composition to achieve desired release profiles, J. Control. Release60 (1999) 379–389.
Search in Google Scholar Back to article
28. K. Ghosal, A. Chandra, R. Rajabalaya, S. Chakraborty and A. Nanda, Mathematical modeling of drug release profiles for modified hydrophobic HPMC based gels, Pharmazie67 (2012) 147–155; DOI: 10.1691/ph.2012.1014.
Search in Google Scholar Back to article
29. T. Oki, S. Maruyama, Y. Takagi, H. I. Yamamura and S. Yamada, Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice, Eur. J. Pharmacol.529 (2006) 157–163; DOI: 10.1016/j.ejphar.2005.11.004.10.1016/j.ejphar.2005.11.00416316647
Search in Google Scholar Back to article

Transdermal delivery of tolterodine tartrate for overactive bladder treatment: In vitro and in vivo evaluation

Abstract

Paradigm

My account